Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Arima Genomics Announces New Study Showing Aventa™ Lymphoma Test Resolves Diagnostic Ambiguity and Guides Care in B-Cell Lymphoma Cases

Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment

Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing that the Aventa Lymphoma test turns ambiguous FISH (fluorescent in situ hybridization) results into clear clinical answers for patients with diffuse large B-cell lymphoma (DLBCL).

Sensitive and precise testing for gene fusions and rearrangements is essential to assure an accurate lymphoma diagnosis. FISH is a widely used, probe-based test that relies on microscopy and interrogates only a single preselected target at a time, whereas Aventa Lymphoma leverages genome-wide Hi-C sequencing to assess all relevant fusions and rearrangements simultaneously in a single assay.

The new study, published in a special issue of the peer-reviewed scientific journal Genes entitledCytogenetics and Cytogenomics in Clinical Diagnostics: Innovations and Applications”, focused on a series of diagnostically challenging cases with atypical FISH findings. The Aventa Lymphoma test confirmed all typical FISH results, while also unambiguously clarifying results where the FISH patterns could not be fully characterized and clinical interpretation remained unclear. Aventa Lymphoma further uncovered additional, clinically consequential rearrangements that were not targeted by FISH testing in all cases investigated --- together shifting diagnoses, refining prognoses, and pointing clinicians to targeted regimens or clinical trials.

“In DLBCL, we often confront patterns that FISH alone can’t fully explain,” said Ying Zou, M.D., Ph.D., Director of Cancer Cytogenetic Laboratory, Cytogenomic Research Core and Associate Director of Molecular Diagnostics Laboratory at Johns Hopkins University, and senior author of the study. “In this study, Aventa Lymphoma delivered the missing context from routine FFPE tissue—clarifying diagnoses and surfacing co-alterations that directly informed risk and potential treatment paths.”

The study details case narratives that show how the broader, unbiased view provided by Aventa Lymphoma provides crucial information that may alter treatment:

  • In one patient with a known MYC rearrangement, the Aventa Lymphoma test identified the partner and demonstrated biology consistent with lower-grade DLBCL rather than the originally suspected high-grade B-cell lymphoma (HGBCL)—altering expectations for risk and treatment intensity.
  • In two other patients, the test detected IGH-driven rearrangements that FISH missed, reclassifying one case as high-risk DLBCL and another as HGBCL.
  • The test also revealed poor prognosis features—TP53 loss and a complex karyotype—that were not apparent from initial testing but could shape therapy selection and follow-up.
  • Several Aventa Lymphoma patient profiles also mapped directly to clinical trial options, turning comprehensive genomic findings into potential next steps.

“Aventa Lymphoma delivers the full genomic picture in a single assay,” said Anthony Schmitt, Ph.D., Senior Vice President, Science, at Arima Genomics. “This study shows we clarified every ambiguous FISH case and uncovered hidden variants that can help clinicians gauge risk and connect patients to appropriate therapies and trials. Our goal is to make this level of clarity routine in lymphoma care.”

About Arima Genomics

Arima Genomics is redefining cancer diagnostics using whole-genome sequence and structure information. Arima’s assays enable a new era of comprehensive, clinically actionable therapy selection insights. The company serves oncologists through its CLIA-certified Aventa clinical testing laboratory in Orlando, Florida, and supports discovery-stage researchers worldwide with advanced kits and informatics. Learn more at www.arimagenomics.com and www.aventatest.com, and follow us on LinkedIn and X.

Our goal is to make this level of clarity routine in lymphoma care.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.